Accessibility navigation


Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes?

Claus, S. P. (2017) Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes? Cell Metabolism, 26 (1). pp. 6-7. ISSN 1550-4131

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1016/j.cmet.2017.06.009

Abstract/Summary

Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Food Microbial Sciences Research Group
ID Code:73545
Publisher:Elsevier

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation